1. Home
  2. GRPN vs SNDX Comparison

GRPN vs SNDX Comparison

Compare GRPN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRPN
  • SNDX
  • Stock Information
  • Founded
  • GRPN 2008
  • SNDX 2005
  • Country
  • GRPN United States
  • SNDX United States
  • Employees
  • GRPN N/A
  • SNDX N/A
  • Industry
  • GRPN Advertising
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRPN Consumer Discretionary
  • SNDX Health Care
  • Exchange
  • GRPN Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • GRPN 1.2B
  • SNDX 1.1B
  • IPO Year
  • GRPN 2011
  • SNDX 2016
  • Fundamental
  • Price
  • GRPN $26.69
  • SNDX $16.24
  • Analyst Decision
  • GRPN Buy
  • SNDX Strong Buy
  • Analyst Count
  • GRPN 4
  • SNDX 10
  • Target Price
  • GRPN $31.25
  • SNDX $37.50
  • AVG Volume (30 Days)
  • GRPN 1.7M
  • SNDX 2.9M
  • Earning Date
  • GRPN 08-06-2025
  • SNDX 08-04-2025
  • Dividend Yield
  • GRPN N/A
  • SNDX N/A
  • EPS Growth
  • GRPN N/A
  • SNDX N/A
  • EPS
  • GRPN N/A
  • SNDX N/A
  • Revenue
  • GRPN $487,747,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • GRPN $3.48
  • SNDX $434.67
  • Revenue Next Year
  • GRPN $8.16
  • SNDX $108.62
  • P/E Ratio
  • GRPN N/A
  • SNDX N/A
  • Revenue Growth
  • GRPN N/A
  • SNDX 2126.66
  • 52 Week Low
  • GRPN $7.75
  • SNDX $8.58
  • 52 Week High
  • GRPN $43.08
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • GRPN 36.21
  • SNDX 79.83
  • Support Level
  • GRPN $26.25
  • SNDX $15.36
  • Resistance Level
  • GRPN $29.52
  • SNDX $16.33
  • Average True Range (ATR)
  • GRPN 2.21
  • SNDX 0.78
  • MACD
  • GRPN -0.44
  • SNDX 0.31
  • Stochastic Oscillator
  • GRPN 2.61
  • SNDX 96.87

About GRPN Groupon Inc.

Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: